Esophageal squamous cell carcinoma is a major histologic subtype of esophageal cancer originating from squamous epithelial cells lining the esophagus. It differs from esophageal adenocarcinoma in epidemiology and risk profile, and remains the dominant subtype in many regions. Disease burden is high in parts of Asia.
The FDA has cleared CStone Pharmaceuticals' investigational new drug application to begin a Phase II trial of its trispecific antibody CS2009 in advanced solid tumors. The multicenter trial will evaluate monotherapy and combination regimens across nine cancer types in Australia, China, and the U.S. Initial Phase I data showed a favorable safety profile and encouraging antitumor activity.
ALX Oncology has multiple 2026 catalysts for Evorpacept and ALX2004. Interim ASPEN-09 data are expected in Q3 2026, while an initial safety update from the phase 1 ALX2004 trial is expected in 1H 2026.
The FDA has approved Agilent's PD-L1 IHC 22C3 pharmDx as a companion diagnostic for identifying esophageal cancer patients eligible for Merck's KEYTRUDA immunotherapy. This marks the eighth FDA-approved indication for this diagnostic test with KEYTRUDA. The test helps identify patients whose tumors express PD-L1 for potential treatment with the anti-PD-1 therapy.
Moffitt Cancer Center researchers published findings on plant-based diets and cancer risk, identified spatial tumor-immune patterns predicting immunotherapy response, and hosted a summit on engineering-driven cancer research innovations.
Izalontamab brengitecan demonstrated statistically significant improvements in progression-free survival and overall survival compared to chemotherapy in patients with previously treated metastatic triple-negative breast cancer, marking the third Phase III success for the bispecific ADC.
CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, in patients with advanced solid tumors across nine cancer indications.
CStone Pharmaceuticals received FDA IND clearance to initiate a Phase II trial of CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors across nine cancer indications.
CStone Pharmaceuticals received FDA IND clearance to begin a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGF, and CTLA-4, in advanced solid tumors across nine cancer indications.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07769658 |
Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma |
NOT_YET_RECRUITING | |
| NCT07745322 |
Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer |
ACTIVE_NOT_RECRUITING | |
| NCT07700667 |
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07699185 |
Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma |
RECRUITING | PHASE2 |
| NCT07697040 |
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC |
NOT_YET_RECRUITING | PHASE1 |
| NCT07686926 |
Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II |
NOT_YET_RECRUITING | PHASE2 |
| NCT07653451 |
Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07629817 |
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy |
RECRUITING | PHASE3 |
| NCT07623642 |
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07618910 |
Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC |
NOT_YET_RECRUITING | PHASE2 |
